SARS-CoV-2 (COVID-19) Spike RBD Neutralizing Antibody [C-A11]

• Catalog Number: orb1274601
• Category: Antibodies
• Description: SARS-CoV-2 (COVID-19) Spike RBD Neutralizing Antibody [C-A11]
• Target: S
• Clonality: Recombinant
• Isotype: IgG1k
• Conjugation: Unconjugated
• Reactivity: Virus
• Form/Appearance: Liquid
• Concentration: batch dependent
• Buffer/Preservatives: 1X PBS
• Purification: Protein A
• Immunogen: recombinant protein (RBD)
• UniProt ID: P0DTC2
• Tested applications: FC, NeA
• Application notes: Functional Assay: This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2. Can be paired with other antibody for detection in sandwich ELISA format.
• Antibody Type: Primary Antibody
• Clone Number: C-A11
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Alternative names: Spike protein S1, Spike protein S2, RBD domain, Bi
• Research Area: Infectious Disease & Virology
• Note: For research use only
• NCBI: P0DTC2

Flow cytometry neutralizing assay: C-A11 displayed dose dependent blocking of spike proteins (wild type and UK variant) to ACE2 expressing cells.

Affinity assessment of SARS-CoV-2 C-A11 IgG to wild type and B.1.1.7 (UK) S1+S2 trimers. C-A11 possesses very low (pM) KD affinity to both variants.

Flow cytomery neutralizing assay of C-A11 (plotted graphs): ACE2 transfected cells were incubated with biotinylated spike protein (0.5 ug/mL) in the presence or absence of antibody. Binding of spike protein was detected with DyLight488 conjugated StreptAvidin. C-A11 efficiently blocked the binding of wild type and UK variant (B.1.1.7) to ACE2 expressing HEK293 cells.

Binding of C-A11 to SARS-CoV-2 variants (UK and South Africa): C-A11 shows good cross reactivity to both variants B.1.1.7 (UK) and B.1.351 (S. Africa).